AIMS: We examined the effect of vascular or Lewy body co-pathologies in subjects with autopsy-confirmed Alzheimer's disease (AD) on the rate of cognitive and functional decline and transition to dementia. METHODS: In an autopsy sample of prospectively characterized subjects from the National Alzheimer's Coordinating Center database, neuropathology diagnosis was used to define the groups of pure AD (pAD, n = 84), mixed vascular and AD (ADV, n = 54), and mixed Lewy body disease and AD (ADLBD, n = 31). Subjects had an initial Clinical Dementia Rating-Global (CDR-G) score <1, Mini-Mental State Examination ≥15, a final visit CDR-G >1, ≥3 evaluations, and Braak tangle stage ≥III. We compared the rate of cognitive and functional decline between the groups. RESULTS: The rate of functional and cognitive decline was lower for ADV, and ADV patients had less severe deficits on CDR-G and the CDR-Sum of Boxes scores at the last visit than pAD and ADLBD patients. No significant differences were noted between ADLBD and pAD patients. After controlling for age at death, the odds of reaching CDR ≥1 at the last visit were lower in the ADV subjects compared to the pAD subjects. CONCLUSIONS: The mean rate of functional and cognitive decline among ADV subjects was slower than among either pAD or ADLBD patients. Vascular pathology did not increase the odds of attaining CDR ≥1 when occurring with AD in this national cohort.
AIMS: We examined the effect of vascular or Lewy body co-pathologies in subjects with autopsy-confirmed Alzheimer's disease (AD) on the rate of cognitive and functional decline and transition to dementia. METHODS: In an autopsy sample of prospectively characterized subjects from the National Alzheimer's Coordinating Center database, neuropathology diagnosis was used to define the groups of pure AD (pAD, n = 84), mixed vascular and AD (ADV, n = 54), and mixed Lewy body disease and AD (ADLBD, n = 31). Subjects had an initial Clinical Dementia Rating-Global (CDR-G) score <1, Mini-Mental State Examination ≥15, a final visit CDR-G >1, ≥3 evaluations, and Braak tangle stage ≥III. We compared the rate of cognitive and functional decline between the groups. RESULTS: The rate of functional and cognitive decline was lower for ADV, and ADV patients had less severe deficits on CDR-G and the CDR-Sum of Boxes scores at the last visit than pAD and ADLBDpatients. No significant differences were noted between ADLBD and pADpatients. After controlling for age at death, the odds of reaching CDR ≥1 at the last visit were lower in the ADV subjects compared to the pAD subjects. CONCLUSIONS: The mean rate of functional and cognitive decline among ADV subjects was slower than among either pAD or ADLBDpatients. Vascular pathology did not increase the odds of attaining CDR ≥1 when occurring with AD in this national cohort.
Authors: Warren W Barker; Cheryl A Luis; Alice Kashuba; Mercy Luis; Dylan G Harwood; David Loewenstein; Carol Waters; Pat Jimison; Eugene Shepherd; Steven Sevush; Neil Graff-Radford; Douglas Newland; Murray Todd; Bayard Miller; Michael Gold; Kenneth Heilman; Leilani Doty; Ira Goodman; Bruce Robinson; Gary Pearl; Dennis Dickson; Ranjan Duara Journal: Alzheimer Dis Assoc Disord Date: 2002 Oct-Dec Impact factor: 2.703
Authors: Lon White; Helen Petrovitch; John Hardman; James Nelson; Daron G Davis; G Webster Ross; Kamal Masaki; Lenore Launer; William R Markesbery Journal: Ann N Y Acad Sci Date: 2002-11 Impact factor: 5.691
Authors: Sarah E Vermeer; Niels D Prins; Tom den Heijer; Albert Hofman; Peter J Koudstaal; Monique M B Breteler Journal: N Engl J Med Date: 2003-03-27 Impact factor: 91.245
Authors: M L Kraybill; E B Larson; D W Tsuang; L Teri; W C McCormick; J D Bowen; W A Kukull; J B Leverenz; M M Cherrier Journal: Neurology Date: 2005-06-28 Impact factor: 9.910
Authors: Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2009 Apr-Jun Impact factor: 2.703
Authors: Prashanthi Vemuri; Timothy G Lesnick; Scott A Przybelski; David S Knopman; Greg M Preboske; Kejal Kantarci; Mekala R Raman; Mary M Machulda; Michelle M Mielke; Val J Lowe; Matthew L Senjem; Jeffrey L Gunter; Walter A Rocca; Rosebud O Roberts; Ronald C Petersen; Clifford R Jack Journal: Brain Date: 2015-01-15 Impact factor: 13.501
Authors: Willa D Brenowitz; Rebecca A Hubbard; C Dirk Keene; Stephen E Hawes; W T Longstreth; Randy L Woltjer; Walter A Kukull Journal: Neurology Date: 2017-09-22 Impact factor: 9.910
Authors: Jagan A Pillai; Maria Khrestian; James Bena; James B Leverenz; Lynn M Bekris Journal: Front Aging Neurosci Date: 2021-06-29 Impact factor: 5.750
Authors: Jagan A Pillai; Mykol Larvie; Jacqueline Chen; Anna Crawford; Jeffery L Cummings; Stephen E Jones Journal: Sci Rep Date: 2020-11-26 Impact factor: 4.379
Authors: Rachel Waller; Ruth Narramore; Julie E Simpson; Paul R Heath; Nikita Verma; Megan Tinsley; Jordan R Barnes; Hanna T Haris; Frances E Henderson; Fiona E Matthews; Connor D Richardson; Carol Brayne; Paul G Ince; Raj N Kalaria; Stephen B Wharton Journal: Brain Pathol Date: 2021-02-15 Impact factor: 7.611